ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESI....FIRO..CY..TRBGCZEEHU..SK....................................*JDIM360 Ver 2.15 (14 Jul 2008) - 2999001/01507529CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120100224W173deBibliographieenBibliographyfrBibliographieEP03732397.9200305162004121720050407enenen381547 P20020517US2010022420100820050223200508200904222009172008111420090531MC20100224201008A61K 31/4184 20060101AFI20031203BHEP A61K 31/19 20060101ALI20031203BHEP C07D 401/12 20060101ALI20031203BHEP A61K 31/44 20060101ALI20031203BHEP A61K 31/196 20060101ALI20031203BHEP deKOMBINATION ENTHALTEND VALSARTAN, AMLODIPIN UND HYDROCHLOROTHIAZIDenCOMBINATION COMPRISING VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDEfrCOMBINAISON COMPRENANT VALSARTANE, AMLODIPINE ET HYDROCHLOROTHIAZIDEWO-A-92/20342DE-A- 10 004 651DE-A- 19 820 151US-A- 5 656 650MACGREGOR G A ET AL: "THE EFFICACY OF CANDESARTAN: AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST ALONE OR IN COMBINATION WITH AMLODIPINE OR IN COMBINATION WITH AMLODIPINE AND HYDROCHLOROTHIAZIDE IN PATIENTS WITH MODERATE-TO-SEVERE ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 10, no. 4, PART 2, April 1997 (1997-04), page 112A XP000869500MACGREGOR G A ET AL: "Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension" HYPERTENSION 2000 UNITED STATES, vol. 36, no. 3, 2000, pages 454-460, XP002251650 ISSN: 0194-911XOPARIL SUZANNE ET AL: "Efficacy and safety of Losartan/Hydrochlorothiazide in patients with severe hypertension." AMERICAN JOURNAL OF CARDIOLOGY, vol. 87, no. 6, 15 March 2001 (2001-03-15), pages 721-726, XP002251651 ISSN: 0002-9149OPARIL SUZANNE ET AL: "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." CLINICAL THERAPEUTICS, vol. 18, no. 4, 1996, pages 608-625, XP002251652 ISSN: 0149-2918OHNISHI K ET AL: "Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: Comparison with a calcium channel blocker." INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 39, no. 10, October 2001 (2001-10), pages 417-422, XP008020851 ISSN: 0946-1965SONG J C, WHITE M: "Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists" PHARMACOTHERAPY, vol. 20, no. 2, 2000, pages 130-139,[Online] Retrieved from the Internet: URL:http://www.pharma.us.novartis.com/news room/pressReleases/releaseDetail.jsp?PRID= 1996>WELLINGTON K, FAULDS D M: "Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension" DRUGS, vol. 62, no. 13, 2002, pages 1983-2005,SHETTY, Suraj, Shivappa12 Spring StreetFar Hills, NJ 07931USWEBB, Randy, Lee17 Honeyman DriveFlemington, NJ 08822USNovartis AG02240429PC/4-32495A/USNLichtstrasse 354056 BaselCHTRBEBGCHCYCZDEDKEEESFIFRGBGRHUIEITLILUMCNLPTROSESISKNovartis Pharma GmbH04273610PC/4-32495A/USNBrunner Strasse 591230 WienATATde Weerd, Petrus G.W.et al00092224Novartis International AG Corporate Intellectual Property4002 BaselCHATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEITLILUMCNLPTROSESISKTREP200300518020030516enWO20030970452003112720034820050223200508